#### **LDE225**

# REAGENTS DIRECT

### 2 mg

## For research purposes only

LDE225 (NPV-LDE225) is a novel and specific small molecule Smoothened (Smo) inhibitor with an IC $_{50}$  of 11nM. LDE225 has been shown to potentially inhibit Hh- and Smo-dependent proliferation in vivo. It also induced the regression of preformed basaloid lesions with an IC $_{50}$  of <150 nmol/l and almost complete regression at 1.5  $\mu$ mol/l. Topical application of a 1% LDE225 solution to depilated skin of C57/BL6 mice completely inhibited hair growth during anagen phase as well as the expression of the Hh-pathway target genes and partial inhibition was obtained when applying a 0.3% solution.

#### **TECHNICAL INFORMATION**

# F<sub>3</sub>CO HN-N-N-N

Other Names: BCP000600/NVP-LDE225/LDE225

Chemical Formula: C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>

**CAS Number:** 956697-53-3

Molecular Weight: 485.5

**Purity: >99%** 

Appearance: white solid

**Solubility: DMSO** 

#### STORAGE AND HANDLING

**Storage:** Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

**Stability:** Stock solutions stable at -20°C for up to 2 years.

**Shipping Conditions:** Shipped at room temperature.

#### **PRODUCT USE**

Soluble in DMSO. If precipitate is observed, vortex for 5 minutes.

#### REFERENCES

- Buonamici et al. (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2 (51):51ra70.
- Skvara et al. (2011) Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 131 (8):1735-44.
- 3. Metcalfe et al. (2011) Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 71(15):5057-61.

